| include ("../../include/busok_leftmenu03.php"); ?> |
|
| HOME > Áø·á°ú/ÀÇ·áÁø¼Ò°³ > Áø·á°ú/ÀÇ·áÁø |
 |
| |
 |
|
| |
Áø·á±³¼ö¾È³» |
|
| |
|
|
| ÀÌ ¸§ |
|
¼Ò °³ |
|
 |
| ±èÁøÀÏ |
|
|
¾à·Â
°æÈñ´ëÇб³ Àǰú´ëÇк´¿ø ºñ´¢±â°ú ±³¼ö
°æÈñ´ëÇб³ µ¿¼ÀÇÇÐ ¿¬±¸¼ÒÀå
°æÈñ´ëÇб³ Àǰú´ëÇÐ ºÎ¼Óº´¿ø Áø·áºÎÀå ¿ªÀÓ
°æÈñ´ëÇб³ Àǰú´ëÇÐ ºÎ¼Óº´¿ø ºñ´¢±â°ú °úÀå ¿ªÀÓ
¹Ì±¹ U. of Penn. º´¿ø, ¼Ò¾Æº´¿ø ¿¬¼ö
¹Ì±¹ º¸½ºÅæ ¼Ò¾Æº´¿ø ¿¬¼ö
Àü¹®Áø·áºÐ¾ß
¼Ò¾Æºñ´¢±â°ú, ¹è´¢Àå¾Ö
ÇÐȸȰµ¿
´ëÇÑ ºñ´¢±â°úÇÐȸ ÀÌ»ç ¿ªÀÓ
´ëÇÑ ¼Ò¾Æºñ´¢±â°úÇÐȸ ÇÐȸÀå ¿ªÀÓ
´ëÇÑ ºñ´¢±â°úÇÐȸ Ãѹ«ÀÌ»ç ¿ªÀÓ |
|
|
|
 |
| À强±¸ |
 |
|
¾à·Â
°æÈñ´ëÇб³ Àǰú´ëÇÐ ºñ´¢±â°ú ±³¼ö
´ëÇѹα¹ ÀÇÇÐÇѸ²¿ø Á¤È¸¿ø
´ëÇÑÀÇ»çÇùȸ ºÎȸÀå
(»ç)°æÈñ-±¹Á¦ÀÇ·áÇù·Âȸ ÀÌ»ç
KBS Çѱ¹¹æ¼Û°ø»ç ÀÚ¹®À§¿ø
Çѱ¹ÀÇÇб³À°Æò°¡¿ø ÀÌ»ç
¹Ì±¹ Roswell Park Cancer Institute ¿¬¼ö
°æÈñ´ëÇб³ ÀǴ뺴¿øÀå ¿ªÀÓ
´ëÇѺñ´¢±âÁ¾¾çÇÐȸ ȸÀå ¿ªÀÓ
¼ö»ó : Á¦5ȸ °úÇбâ¼ú ¿ì¼ö³í¹®»ó
°íȲÀÇÇлó(±Ý, Àº, µ¿»ó) ¼ö»ó
±³À°ºÎ Àå°ü»ó
¿©ÁÖ ¹®È»ó Çмú»ó
Àü¹®Áø·áºÐ¾ß
ºñ´¢±â »ý½Ä°èÁ¾¾ç(¾Ï), ½ÅÀåÀ̽ÄÇÐ
ÇÐȸȰµ¿
´ëÇѺñ´¢±âÁ¾¾çÇÐȸ ȸÀå
´ëÇÑ ¾ÏÇÐȸ Ãѹ«ÀÌ»ç ¿ªÀÓ
´ëÇÑ ¾ÏÇÐȸ À繫À§¿øÀå ¿ªÀÓ
´ëÇÑ ºñ´¢±â°úÇÐȸ ¼ö·ÃÀ§¿øÀå ¿ªÀÓ
´ëÇÑ ºñ´¢±â°úÇÐȸ À繫À§¿øÀå ¿ªÀÓ
´ëÇÑ ºñ´¢±â°úÇÐȸ Ãѹ«ÀÌ»ç ¿ªÀÓ
´ëÇÑ ºñ´¢±âÁ¾¾çÇÐȸ ÆíÁýÀ§¿øÀå ¿ªÀÓ
¹Ì±¹ ºñ´¢±â°úÇÐȸ Á¤È¸¿ø
¹Ì±¹ ¾Ï¿¬±¸ÇÐȸ Á¤È¸¿ø
±¹Á¦ ºñ´¢±â°úÇÐȸ Á¤È¸¿ø
´ëÇÑ ¾ÏÇÐȸ ºÎȸÀå |
|
|
|
 |
| ÀÌÃæÇö |
|
|
¾à·Â
°æÈñ´ëÇб³ Àǰú´ëÇÐ ºñ´¢±â°ú ±³¼ö
°æÈñ´ëÇб³ Àǰú´ëÇÐ ºñ´¢±â°ú °úÀå
George Town University(¹Ì Washington DC) ¿¬¼ö
°æÈñ´ëÇб³ Àǰú´ëÇÐ µ¿¹®È¸ ÇмúÀÌ»ç
°æÈñ´ëÇб³ ´ëÇпø µ¿¹®È¸ ÇмúÀÌ»ç
Àü¹®Áø·áºÐ¾ß
³²¼º°úÇÐ, ³²¼ººÒÀÓ
ÇÐȸȰµ¿
´ëÇѺñ´¢±â°úÇÐȸÀÌ»ç
´ëÇѺñ´¢±â°úÇÐȸ °í½ÃÀ§¿ø
´ëÇѺñ´¢±â°úÇÐȸ ÆíÁýÀ§¿ø ¿ªÀÓ
´ëÇѳ²¼º°úÇÐȸ ÀÌ»ç
´ëÇѺñ´¢±â°úÇÐȸ Á¤È¸¿ø |
|
|
|
 |
| À̼±ÁÖ |
|
|
¾à·Â
°æÈñ´ëÇб³ Àǰú´ëÇÐ ºñ´¢±â°ú ºÎ±³¼ö
°æÈñ´ëÇб³ Àǰú´ëÇк´¿ø ºñ´¢±â°ú °úÀå
Univ. of Pittsburgh ¿¬¼ö
Àü¹®Áø·áºÐ¾ß
¿©¼º¿ä½Ç±Ý, ¹è´¢Áúȯ, ¿ä·Î°á¼®
ÇÐȸȰµ¿
´ëÇѺñ´¢±â°úÇÐȸ Á¤È¸¿ø
´ëÇÑ ¿ä½Ç±Ý ¹è´¢Àå¾ÖÇÐȸ ÀÌ»ç
´ëÇÑ ¿ä½Ç±Ý ¹è´¢Àå¾ÖÇÐȸ LUTS ÇмúÁö ÆíÁýÀ§¿ø
´ëÇÑ ¿ä·Î»ý½Ä±â °¨¿°ÇÐȸ ´ë¿ÜÇù·Â ÀÌ»ç
¹Ì±¹ºñ´¢±â°úÇÐȸ Correspoding Member
Society for Neuroscience Á¤È¸¿ø |
|
|
|
 |
| Àü½ÂÇö |
|
|
¾à·Â
°æÈñ´ëÇб³ Àǰú´ëÇÐ ºñ´¢±â°ú ºÎ±³¼ö
ÀϺ» ³ª°í¾ß ±¹¸³´ëÇÐ ÀÇÇкΠºñ´¢±â°ú º¹°°æ¼ö¼ú ¿¬¼ö
¹Ì±¹ Florida Hospital Global Robotics Institute ·Îº¿¼ö¼ú ¿¬¼ö
Àü¹®Áø·áºÐ¾ß
ºñ´¢±âÁ¾¾ç (Àü¸³¼±¾Ï, ½ÅÀå¾Ï, ¹æ±¤¾Ï), ·Îº¿¼ö¼ú, º¹°°æ¼ö¼ú
ÇÐȸȰµ¿
´ëÇѺñ´¢±â°úÇÐȸ Á¤È¸¿ø
ÀϺ» Endourology & ESWL ÇÐȸ Á¤È¸¿ø
´ëÇѺñ´¢±â°úÇÐȸ À±¸®Çù·ÂÀ§¿ø
´ëÇѺñ´¢±â°úÇÐȸ ±¹Á¦±³·ùÀ§¿ø
´ëÇѺñ´¢±âÁ¾¾çÇÐȸ ÀÌ»ç
´ëÇѺñ´¢±âÁ¾¾çÇÐȸ ÆíÁýÀ§¿ø
´ëÇѺñ´¢±âÁ¾¾çÇÐȸ º¸ÇèÀ§¿ø
´ëÇѺñ´¢±âÁ¾¾çÇÐȸ ±³À°À§¿ø
´ëÇÑ EndourologyÇÐȸ ÀÌ»ç
´ëÇÑ EndourologyÇÐȸ ÇмúÀ§¿ø
´ëÇÑ EndourologyÇÐȸ ¿¬±¸À§¿ø
|
|
|
|
|
|
| |
|
|
| |
°ú¼Ò°³ |
|
| |
|
|
 |
°æÈñ´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø º´¿ø ºñ´¢±â°ú¸¦ ¹æ¹®ÇÏ¿© ÁֽаÍÀ» ±â»Ú°Ô »ý°¢ÇÕ´Ï´Ù. ºñ´¢±â°ú´Â ¼Òº¯ÀÌ ¸¸µé¾îÁö°í ü¿Ü·Î ¹èÃâµÇ´Â ±â°üÀÎ ½ÅÀå, ½Å¿ì, ¿ä°ü, ¹æ±¤ ¹× ¿äµµµîÀÇ Àå±â¿Í ³²¼º¿¡¼´Â Àü¸³¼±, Á¤³¶ Á¤°ü °íȯ ¹× À½°æµî »ý½Ä±â °èÅë°ú ¿©¼º¿¡¼´Â ¿ä½Ç±Ý ¹× ¹è´¢Àå¾Ö ¿©¼º ¼º±â´ÉÀå¾Ö¸¦ ´ã´çÇϰí ÀÖ´Â °úÀÔ´Ï´Ù.
Çѱ¹ ºñ´¢±â°ú¸¦ ¼±µµÀûÀ¸·Î À̲ø°í ÀÖ´Â º» ºñ´¢±â°ú´Â Áúº´À» Ä¡·áÇϱâ À§ÇÏ¿© Áø·á¿Í ¿¬±¸¿¡ ¸ÅÁøÇϰí ÀÖÀ¸¸ç ´õ ÀÚ¼¼ÇÑ ³»¿ëÀº ´ÙÀ½ÀÇ Á¤º¸¸¦ Âü°í ÇϽñ⠹ٶø´Ï´Ù.
ºñ´¢±â°ú¸¦ ¹æ¹®ÇØ ÁֽаÍÀ» ´Ù½Ã Çѹø °¨»çÇÏ°Ô »ý°¢ÇÏ¸ç º» »çÀÌÆ®¿¡¼ À¯ÀÍÇÑ Á¤º¸¸¦ ¾òÀ¸½Ã±æ ¹Ù¶ø´Ï´Ù.
ºñ´¢±â°ú ±¸¼º |
 |
Àü°øÀÇ
¿Ü·¡ ¹× ÀÔ¿ø ȯÀÚµéÀ» ±³¼ö´Ô Áöµµ ÇÏ¿¡ µ¹º¸°í ÀÖ´Â ºñ´¢±â°ú ÀÇ»çµé·Î ȯÀÚÄ¡·á¿Í ´õºÒ¾î ¿¬±¸È°µ¿°ú ³í¹®¹ßÇ¥¿¡ ¸ÅÁøÇϰí ÀÖ´Ù. |
 |
¼â¼®½Ç
1987³âµµºÎÅÍ Ã¼¿ÜÃæ°ÝÆÄ¼â¼®±â¸¦ µµÀÔÇÏ¿© ¼±µµÀûÀ¸·Î °á¼® Ä¡·á¿¡ ¾ÕÀå¼°í ÀÖÀ¸¸ç, 2002³âµµ¿¡´Â ÇÁ¶û½º ¿¡´äÅ×Å©³ë¸Þµå»ç·Î ºÎÅÍ ±âÁ¸¿¡ »ç¿ëÇϰí Àִ Ÿ±âÁ¾µéÀÇ °áÁ¡À» ÇÑÃþ º¸¿ÏÇÑ Á¦4¼¼´ëÀÇ ÃÖ½ÅÇü¼â¼®±âÀÎ SONOLITH Praktis¸¦ µµÀÔÇÔÀ¸·Î½á Á¾·¡ÀÇ Àý°³ ¼ö¼úÀ̳ª °æÇÇÀû ¼â¼®¼ú¿¡ ºñÇØ º¸´Ù ¾ÈÀüÇÏ°í °æÁ¦ÀûÀ̸ç, ÇǺΠÀý°³³ª ÅëÁõ¾øÀÌ Ä¡·á ÇÒ ¼ö ÀÖ°Ô µÇ¾ú´Ù.
|
 |
¹æ±¤°æ½Ç
³»½Ã°æÀ» ÀÌ¿ëÇÏ¿© ¿ä·Î ¹× ¹æ±¤¿¡ ÀÌ»ó À¯¹«¸¦ °Ë»çÇÏ´Â °÷ |
 |
º¹°°æ ¼ö¼ú
º¹ºÎ¸¦ Àý°³ÇÏÁö ¾Ê°í, º¹ºÎ¿¡ ÃÖ¼ÒÇÑÀÇ Àý°³°ø 3~5°³¸¦ ¶Õ¾î ÀÌ ±¸¸Û¿¡ Ư¼ö ±â±¸µéÀ» ³Ö¾î ¸ð´ÏÅ͸¦ º¸¸é¼ ¼¶¼¼Çϰí Á¤¹ÐÇÏ°Ô ¼ö¼úÇÏ´Â °ÍÀ¸·Î ±âÁ¸ÀÇ °³º¹¼ö¼ú¿¡ ºñÇØ ÅëÁõÀ̳ª ÃâÇ÷, °¨¿°ÀÇ À§ÇèÀÌ °ÅÀÇ ¾øÀ» »Ó¸¸ ¾Æ´Ï¶ó ¼ö¼ú ÈÄ È¸º¹ÀÌ ¸Å¿ì ºü¸£°í ¼ö¼úºÎÀ§°¡ ÈäÇÏÁö ¾Ê¾Æ ¹Ì¿ë¿¡µµ ÁÁ½À´Ï´Ù. |
 |
ºñµð¿À ¿ä¿ªµ¿ °Ë»ç
½Å°æÀμº¹æ±¤, ¿ä½Ç±Ý µî ¹è´¢ Áõ»óÀ» È£¼ÒÇϴ ȯÀÚ¿¡¼ ¿øÀÎÀ» ¹àÈ÷´Â Áß¿äÇÑ °Ë»ç·Î¼ x-ray Åõ½Ã±â¸¦ ÅëÇØ ¹æ±¤ ¹× ¿äµµÀÇ ¸ð¾ç°ú ¾Ð·ÂÀ» µ¿½Ã¿¡ ½Ç½Ã°£À¸·Î ÃøÁ¤ÇÒ ¼ö ÀÖ´Â ÃÖ÷´Ü °Ë»ç±âÀÔ´Ï´Ù. |
 |
¼º±â´É °Ë»ç½Ç
¹ß±âºÎÀü ¹× ¼º±â´É Àå¾Ö¿¡ ´ëÇØ ½Ãû°¢°Ë»ç¿Í ½Å°æ°Ë»çµîÀ» µ¿½Ã¿¡ ½ÃÇàÇÏ¿© ȯÀڵ鿡°Ô ÈÇ·æÇÑ Ä¡·á½ÇÀûÀ» º¸À̰í ÀÖ´Ù. |
 |
¼Ò¼ö¼ú½Ç
°íȯ»ý°Ë, Á¤°ü¼ö¼ú, Æ÷°æ¼ö¼ú °£´ÜÇÑ ¼ö¼úÀ» ½ÃÇàÇÑ´Ù. |
 |
ºñ´¢±â°ú ½ÇÇè½Ç
±âÃÊ ½ÇÇè ¹× µ¿¹° ½ÇÇèÀ» ÅëÇÏ¿© ºñ´¢±â°úÇÐ ±âÃÊ¿¬±¸¸¦ ÁøÇàÇϰí ÀÖ´Ù. |
 |
ºñ´¢±â°úÀÇ °ú°Å, ÇöÀç ±×¸®°í ¹Ì·¡
1965³â 12¿ù °æÈñ´ëÇб³ Àǰú´ëÇÐÀÌ ½Å¼³µÇ¾úÀ¸¸ç,
1971³â 4¿ù ÇÑÀϺ´¿ø ºñ´¢±â°ú °úÀåÀ¸·Î ÀçÁ÷ ÁßÀÌ´ø ±èÅÂÁø ºÎ±³¼ö°¡ ºñ´¢±â°ú ÃÊ´ë ÁÖÀÓ±³¼ö·Î ºÎÀÓÇÏ¿´°í, °°Àº ÇØ 8¿ù ä¼öÀÀ Á¶±³¼ö°¡ ºÎÀÓÇÏ¿© °æÈñÀÇ´ë ºñ´¢±â°úÇб³½ÇÀÇ ÃÊ´ë ±³¼öÁøÀ» ÀÌ·ç¾ú´Ù.
1971³â 10¿ù 5ÀÏ ´ç½Ã 30 ¿©¾ï¿øÀÇ °ÇÃàºñ¸¦ ÅõÀÚÇϰí 18ÃþÀÇ Çö´ë½Ä °Ç¹°°ú ÃֽŠÀÇ·á Àåºñ¸¦ °®Ãá °æÈñÀÇ´ë ºÎ¼Óº´¿øÀÇ °³¿ø°ú µ¿½Ã¿¡ ºñ´¢±â°ú°¡ °³¼³µÇ¾ú´Ù.
1978³â 8¿ù 30ÀÏ¿¡´Â ½ÅÀåÀÌ½Ä ¼ö¼ú¿¡ ¼º°øÇÏ¿´°í, 1979³â 5¿ù¿¡´Â ij³ª´Ù McGill ´ëÇк´¿ø¿¡¼ 2³â°£ ¿¬¼ö¸¦ ¸¶Ä£ ÃÖȲ Á¶±³¼ö°¡ ºÎÀÓÇÏ¿© ±³¼öÁø¿ëÀÌ ÇÑÃþ °ÈµÇ¾ú´Ù.
1978³â 11¿ù 27ÀÏ¿¡´Â ±¹³» ÃÖÃÊ·Î ¹æ±¤°æ Àåºñ¸¦, 1980³â 1¿ù 31ÀÏ¿¡´Â X-ray°¡ ºÎÂøµÈ ºñ´¢±â°ú¼ö¼ú Å×À̺íÀ» µµÀÔÇÏ¿© ´ç½Ã·Î´Â ÃÖ÷´ÜÀÇ Áø·á Àåºñ¸¦ °®Ãß°Ô µÇ¾ú´Ù.
1981³â 10¿ù 20ÀÏ¿¡´Â ¿ä·ù¿ªÇа˻ç±â¸¦ µµÀÔÇÏ¿© ½Å°æÀμº¹æ±¤È¯ÀÚ Áø·á¿¡ ÀÏ´ë Àü±â°¡ µÇ¾ú´Ù.
1982³â 5¿ù¿¡´Â ±èÁøÀÏ ÀÓ»ó°»ç°¡ ºÎÀÓÇÏ¿´°í, 1983³â 3¿ù ä¼öÀÀ ±³¼ö°¡ Á¦ 2´ë ºñ´¢±â°ú ÁÖÀÓ±³¼ö ¹× °úÀå¿¡ ÀÓ¸íµÇ¾ú´Ù.
1986³â 3¿ù ÇѸ²ÀÇ´ë¿¡¼ ÀçÁ÷ ÁßÀÌ´ø À强±¸ ÀüÀÓ°»ç°¡ ºÎÀÓÇÏ¿´´Ù.
1987³â 5¿ù 25ÀÏ¿¡´Â ü¿ÜÃæ°ÝÆÄ¼â¼®±â(Edap LT01)¸¦ °¡µ¿ÇÏ°Ô µÇ¾ú°í 10¿ù 21¿¡´Â ¿ä°ü°æ ¹× °æÇÇÀû½Å¼â¼®¼ú¿¡ ÇÊ¿äÇÑ set¸¦ µµÀÔÇÏ¿© ¸í½Ç»óºÎÇÑ °á¼®Ä¡·á¼¾ÅÍÀÇ ¿î¿µÀÌ ½ÃÀ۵Ǿú´Ù.
1988³â 3¿ù¿¡´Â µ¿¼ö¿øº´¿ø ºñ´¢±â°ú °úÀåÀ¸·Î ±Ù¹«ÇÏ´ø ÀÌÃæÇö ÀÓ»ó°»ç°¡ ºÎÀÓÇÏ¿´´Ù.
1988³â¿¡´Â ÀÔ¿ø ȯÀÚ ¼ö°¡ 1021¸í, ¼ö¼ú 445¸íÀ̾úÀ¸¸ç ½ÅÀ̽ļúÀÌ 100·Ê¸¦ µ¹ÆÄÇÏ¿´´Ù.
1990³â 8¿ù¿¡´Â ÃÖ÷´Ü Áø´ÜÀåºñ¸¦ µµÀÔÇÏ¿© ¼º±â´ÉÀå¾ÖŬ¸®´ÐÀ» °¡µ¿ÇÏ¿´´Ù.
1994³â 4¿ù ±èÁøÀÏ ±³¼ö°¡ Á¦ 3´ë ºñ´¢±â°ú ÁÖÀÓ±³¼ö ¹× °úÀå¿¡ ÀÓ¸íµÇ¾ú´Ù.
1994³â 5¿ù¿¡´Â Á¦ÁÖÀÇ·á¿ø ºñ´¢±â°ú °úÀåÀ¸·Î °øÁߺ¸°ÇÀǸ¦ ¸¶Ä£ À̼±ÁÖ ÀÓ»ó°»ç°¡ ºÎÀÓÇÏ¿´´Ù.
1997³â 9¿ù¿¡´Â Àü¸³¼±±ØÃÊ´ÜÆÄÄ¡·á±â (Prostatron 2.5, EDAP)°¡ µµÀԵŠ´Ù¾çÇÑ Àü¸³¼±ºñ´ëÁõÄ¡·á¹ýÀ» ½ÃÇàÇÒ ¼ö ÀÖ°Ô µÇ¾ú´Ù.
2002³â 3¿ù¿¡´Â ºÎõ¼¼Á¾º´¿ø ºñ´¢±â°ú °úÀåÀ¸·Î ±Ù¹«ÇÏ´ø Àü½ÂÇö ÀÓ»ó°»ç°¡ ºÎÀÓÇÏ¿´´Ù.
2002³â 11¿ù¿¡´Â ÃÖ÷´Ü ü¿ÜÃæ°ÝÆÄ¼â¼®±â (Sonovision)°¡ µµÀÔµÇ¾î ¿ì¼öÇÑ Ä¡·á¸¦ Á¦°øÇϰí ÀÖ´Ù.
2003³â 3¿ùºÎÅÍ 2004³â 2¿ù±îÁö 1³â°£ Àü½ÂÇö ÀÓ»ó°»ç°¡ ÀϺ» ±¹¸³ ³ª°í¾ß ´ëÇÐ ÀÇÇкΠºñ´¢±â°ú¿¡¼ ÃֽŠºñ´¢±â°ú º¹°°æ¼ö¼úÀ» ¿¬¼öÇÏ¿´´Ù.
2004³â 2¿ù¿¡´Â ÃÖ½ÅÀÇ º¹°°æ ¼ö¼ú±â±¸°¡ µµÀÔµÇ¾î ºñ´¢±â°ú ¼ö¼ú¿µ¿ª¿¡ ÀÖ¾î ÃÖ÷´ÜÀ» °È°Ô µÇ¾ú´Ù.
2005³â 1¿ù À强±¸ ±³¼ö°¡ °æÈñÀÇ·á¿ø ±âȹÁ¶Á¤½ÇÀåÀ¸·Î ÀÓ¸íµÇ¾ú´Ù.
2005³â 1¿ù ÀÌÃæÇö ±³¼ö°¡ ºñ´¢±â°ú °úÀå¿¡ ÀÓ¸íµÇ¾ú´Ù.
2006³â 3¿ù ÀÓ»óÁ¶±³¼ö·Î ±Ù¹«ÇÏ´ø Àü½ÂÇö±³¼ö°¡ µ¿¼½ÅÀÇÇк´¿ø Á¶±³¼ö·Î ÀüÀÓÇÏ¿´´Ù.
2008³â 3¿ù À强±¸ ±³¼ö°¡ °æÈñÀÇ·á¿ø ºÎ¼Ó º´¿øÀå¿¡ ÀÓ¸íµÇ¾ú´Ù.
2009³â 2¿ù ÃÖ÷´Ü ¼ö¼ú¿ë ·Îº¿ '´ÙºóÄ¡'¸¦ µµÀÔÇÏ¿´°í, ù ·Îº¿ Àü¸³¼± ÀüÀûÃâ¼úÀ» ½ÃÇàÇÏ¿´´Ù.
2009³â 3¿ù °æÈñµ¿¼½ÅÀÇÇк´¿ø ºñ´¢±â°ú Á¶±³¼ö·Î ±Ù¹«ÇÏ´ø Àü½ÂÇö Á¶±³¼ö°¡ ºÎÀÓÇÏ¿´´Ù.
2009³â 12¿ù 31ÀÏ ·Îº¿ µµÀÔ 11°³¿ù ¸¸¿¡ ºñ´¢±â°ú ·Îº¿ ¼ö¼ú ÃÑ47·Ê¸¦ ´Þ¼ºÇÏ¿´´Ù.
2010³â 6¿ù 1ÀÏ À̼±ÁÖ ±³¼ö°¡ ºñ´¢±â°ú °úÀå¿¡ ÀÓ¸íµÇ¾ú´Ù.
>>ÇöÀç¿Í ¹Ì·¡ÀÇ ºñ´¢±â°ú
º»°ú´Â 1993³â ´ç½Ã 1¾ï 5õ¸¸¿øÀÇ Æ¯Áøºñ¸¦ µé¿© Àåºñ ¹× ½Ã¾àÀ» ±¸ÀÔÇÏ°í ºñ´¢±â°ú ½ÇÇè½ÇÀ» °³¼³Çѹ٠ÀÖ´Ù.
ÀÌ´Â °æÈñÀÇ´ë ºñ´¢±â°úÀÇ ¿¬±¸¼öÁØÀ» ³ôÀ̱â À§ÇØ ¹Ì·¡¸¦ ³»´Ù º» ¾È¸ñÀÖ´Â ÅõÀÚ¿´´Ù.
ÀÌ·¯ÇÑ ÁøÃëÀûÀÎ ¿¬±¸ÀÇÁö°¡ ¹Ø¹ÙÅÁÀÌ µÇ¾î ÇöÀç Ȱ¹ßÇÏ°Ô SCI(scientific citration index) ÇмúÁö¿¡ ³í¹® °ÔÁ¦¸¦ Çϰí ÀÖÀ¸¸ç ¶ÇÇÑ Àú¸í ¿Ü±¹Çмú´ëȸ¿¡¼ ³í¹® ¹ßÇ¥¸¦ ¼±µµÇϰí ÀÖ´Ù.
¶ÇÇÑ ÀÌ·¯ÇÑ ¿¬±¸¾÷ÀûÀ» ¹ÙÅÁÀ¸·Î Çб³ ¹× ±¹°¡´Üü·ÎºÎÅÍ ¿¬±¸ºñ¸¦ ¼öÇý¹Þ°í ÀÖÀ¸¸ç, ¸¹Àº Çмúǥâ»ó°ú °ø·Î»óÀ» ¹ÞÀº¹Ù ÀÖ´Ù.
º»°ú´Â ÀÌ·¯ÇÑ Çмú ¹× Áø·á¼º°ú¿¡ ¸¸Á·Ä¡ ¾Ê°í º¸´Ù ¹Ì·¡ÁöÇâÀûÀÎ ºñÀüÀ» °¡Áö°í ¼¼°è ºñ´¢±â°ú Çа踦 ¼±µµÇÒ Çмú ¹× Áø·á¸¦ ÁغñÇϰí ÀÖ´Ù.
ÀÌ´Â º»±³ÀÇ Ã¢ÇÐ À̳ä°úµµ ÀÏÄ¡ÇÏ´Â °ÍÀÌ´Ù.
¿¬±¸ºñ ¼öÇý ½ÇÀû
1. º¸°Çº¹ÁöºÎ - ½Å¾à°³¹ß¿¬±¸ »ç¾÷ ÃÑ¿¬±¸ºñ (3¾ï5õ3¹é¸¸¿ø)
2. º¸°ÇÀÇ·á±â¼ú ¿¬±¸ °³¹ß »ç¾÷´Ü ±Ý¾× (2¾ï)
3. ¾ÏÁ¤º¹ ÃßÁø ¿¬±¸°³¹ß »ç¾÷ : ½Å¼¼Æ÷¾Ï Á¶±âÁø´Ü kitÀÇ °³¹ß¿¡ °üÇÑ ¿¬±¸(1¾ï¿ø)
4. º¸°Çº¹ÁöºÎ(»ç¾÷¸í-º¸°ÇÀÇ·á±â¼ú ¿¬±¸°³¹ß»ç¾÷): Cyclophillin A¿Í °áÇÕÇÏ¿© Ç×»êÈ ÀÛ¿ëÀ» º¸ÀÌ´Â ´Ü¹éÁú¿¡ °üÇÑ ¿¬±¸ (5700¸¸¿ø)
5. °úÇбâ¼úó(°úÇÐÀç´Ü) : Medical Science and Engineering Research Center(MRC) - 2000 ¸¸¿ø(ÃÑ: 6¾ï8õ ¸¸¿ø)
6. »êÇÐ ¿¬±¸ºñ: ¹æ±¤¾Ï ȯÀÚ¿¡¼ telomerase ÃøÁ¤ÀÌ ¿¹ÈÄ ¹× ¼±º° °Ë»ç·Î¼ÀÇ ¿ªÇÒÀ» Çϴ°¡? (600¸¸¿ø)
7. »êÇÐÇùµ¿ ¿¬±¸ºñ(MSD Korea): prostate symptom scoreÀÇ Çѱ¹Çü ¼³¹®Áö °³¹ß (300¸¸¿ø)
8. ±× ¿Ü ±³³», µ¿¼ÀÇÇÐ ¿¬±¸ºñ ´Ù¼ö
±¹¿Ü Àü¹®ÇмúÁö( SCI Registered Journal ) ¿¡ ½Ç¸° ³í¹®
1. Preventive effectc of hyaluronic acid on Escherichia coli-induced urinary tract infection in rat. Urology. 2010;75:949-54.
2. Neuroanatomical study of periprostatic nerve distribution using human cadaver prostate. J Korean Med Sci. 2010;25:608-12.
3. Efficacy and Safety of Tamsulosin for the Treatment of Non-neurogenic Voiding Dysfunction in Females: A 8-Week Prospective Study. J Korean Med Sci. 2010 ;25:117-22.
4. Comparison of urodynamics between ischemic and hemorrhagic stroke patients; can we suggest the category of urinary dysfunction in patients with cerebrovascular accident according to type of stroke?. Neurourol Urodyn. 2010;29:387-90.
5. Vasectomy is not a simple procedure: Subtotal testicular infarction. Scand J Urol Nephrol. 2010.
6. Effect of dominant hemispheric stroke on detrusor function in patients with lower urinary tract symptoms. Int J Urol. 2010.
7. Acute Pyelonephritis: Clinical Characteristics and the Role of the Surgical Treatment. J Korean Med Sci. 2009;24:296-301.
8. Effects of tissue-cultured mountain ginseng (Panax ginseng CA Meyer) extract on male patients with erectile dysfunction.Asian J Androl. 2009;11:356-61.
9. Lymphatic vessel densities of lymph node-negative prostate adenocarcinoma in Korea. Pathol Res Pract. 2009;205:249-54.
10. How many cases are necessary to develop competence for laparoscopic radical nephrectomy? J Endourol. 2009;23:1965-9.
11. Dystrophic calcification and stone formation on the entire bladder neck after potassium-titanyl phosphate laser vaporization for the prostate: A case report J Korean Med Sci. 2009;24:741-3.
12. Preventive effects of hyaluronic acid on Escherichia coli-induced urinary tract infection in rat. Urology. 2010;75:949-54.
13. Differences in tumor characteristics and prognosis in newly diagnosed Ta, T1 urothelial carcinoma of bladder according to patient age. Urology. 2009 ;73:828-32.
14. Simple renal cyst sclerotherapy with acetic acid: our 10-year experience. J Endourol. 2008;22:2559-63.
15. Villous adenoma of the urinary bladder, Int J Urol. 2008;15:551-3.
16. Correlation of the erectile dysfunction with lesions of cerebrovascular accident. Urology. 2008;71:99-103.
17. 5-HT1A receptor-mediated activation of a G-protein-coupled inwardly rectifying K current in rat medial preoptic area neuron. Eur J Pharmacol. 2008;586:114-22.
18. Efficacy of the Sonolith Vision Lithotripter according to the electrode lifespan: an in vitro study. J Endourol. 2008;22:735-8.
19. Serotonergic modulation of GABAergic and glutamatergic synaptic transmission in mechnically isolated rat medial preoptic area neurons. Neuropsychopharmacology. 2008;33:340-52.
20. Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses. Oncogene. 2006;25:5807-22.
21. Expression of functional nicotinic acetylcholine receptors in rat urinary bladder epithelial cells.. Am J Physiol Renal Physiol. 2006;290:103-10.
22. Is chronic inflammatory change in the prostate the major cause of rising serum prostate-specific antigen in patients with clinical suspicion of prostate cancer?. Int J Urol. 2006;13:122-6.
23. Efficacy of Combined Gemcitabine/Cisplatin Chemotherapy for Loclly Advanced or Metastatic Urothelial Cancer. Cancer Res Treat. 2006;38:78-83
24. Outcome of nephrectomy and kidney-preserving procedures for the treatment of emphysematous pyelonephritis. Scand J Urol Nephrol 2006;40:332-8.
25. Treatment of infected urachal cysts. Yonsei Med J. 2006;47:423-7.
26. Clinical prognostic factors for radical cystectomy in bladder cancer. Cancer Res Treat. 2005;37:48-53
27. Long-term follow-up of ureteral stump tumors after nephrectomy for benign renal disease. Eur Urol. 2004;46:748-52.
28. Complete duplication of bladder and urethra in coronal plane with no other anomalies: case report with review of the literature. Review Urology. 2005;65:388.
29. Delayed hemorrhage from a pseudoaneurysm after blunt renal trauma. Int J Urol. 2005;12:909-11.
30. Prednisolone suppresses cyclosporin A-induced apoptosis but not cell cycle arrest in MDCK cells. Arch Biochem Biophys. 2005;435:382-92.
31. Clinical characteristics of renal transplant recipients that underwent urologic surgery for de novo disease before and after transplantation. J Korean Med Sci. 2005;20:75-8.
32. Glucose transporter-1 expression in urothelial papilloma of the bladder. Urol Int. 2005;74:268-71.
33. Arteriovenous malformation of the urinary bladder: Treated by transurethral resection. Int J Urol. 2005;12:409-11.
34. The Bulbous Urethra Involved in Perineal Extraskeletal Myxoid Chondrosarcoma in a Child : case report. Int. J Urol. in press 2004.
35. Infravesical Obstruction Due to Benign Intraurethral Prostatic Cyst. J Korean Med Sci. 2003;18:125-26.
36. Factors influencing contralateral renal hypertrophy after living donor nephrectomy. Transplant P. 2002;34:1139-42.
37. Anticancer cytotoxicity and nephrotoxicity of the new platinum(II) complexes containing diaminocyclohexane and glycolic acid. Int J Oncol. 2002;20:929-35.
38. Frequent epigenetic inactivation of rassf1 a in human bladder carcinoma. Cancer Res. 2001;61:6688-92.
39. Clinical Significance of Urinary Vascular Endothelial Growth Factor and Microvessel Density in Patient with Renal Cell Carcinoma. Urology. 2001;58:904-81.
40. Clinical Significance of Urinary Vascular Endothelial Growth Factor in Patient with Superficial Bladder Tumor. Oncol Rep. 2001;8:1265-67.
41. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy. Oncol Rep. 2001;8:257-61.
42. Treatment of Prostatic Abscess : Value of Transrectal Ultrasonographycally Guided Needle Aspiration. J Ultras Med. 2000;19:609-17.
43. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res. 2000;60:3370-74.
44. Acetic acid as a sclerosing agent for renal cyst : Comparison with ethanol in follow-up results. Cardiovasc Inter Rad. 2000;23:177-81.
45. Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. Urology. 2000;55:448-52.
46. Hypericin induces both differentiation and apoptosis in human promyelocytic leukemia HL-60 cells. Biol. Pharm. Bull. 1999;22:1271-74.
47. Mannan-binding lectin(MBL)-associated plasma protein present in human urine inhibits calcium oxalate crystal growth. FEBS Lett. 1999;462:89-93.
48. The role for adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma. Anticancer Res. 1999;19:5593-97.
49. Clinical study of insuline-like growth factor-1 and compensatory renal growth in patients with donor nephrectomy. Transplant P. 1999;31:2114-17.
50. Elevated and biallelic expression of p73 is associated with progression of human bladder cancer. Cancer Res. 1999;59:2791-93.
51. Efficacy of new platinum analog DPPE in an orthotopic nude mouse model of human colon cancer. Anticancer Res. 1999;19:157-61.
52. Cytokine production in primary histoculture by human normal kidney, renal cell carcinoma and benign renal angiomyolipoma tissues. Anticancer Res. 1998;18:4195-200.
53. Antimetastatic activity of the new platinum analog [Pt (cis-dach) (DPPE)?2NO3] in a metastatic model of human bladder cancer. Anticancer Res. 1997;17:3239-42.
54. Antitumor activity and nephrotoxicity of a novel platinum complexes, [ 1,3-bis(diphenyl phosphino)propane](trans-l-dach)platinum(II)dinitrate. Anticancer Res. 1997;17:995-60.
55. Interleukin-6 production in primary histoculture by normal human kidney and renal tumor tissues. Anticancer Res. 1997;17:113-16.
56. Screening of the differentially expressed genes in human renal oncocytoma. Mol Cells. 1996;6:637-44.
57. Efficacy of the platinum analog { Pt ( cis - dach )( DPPE )?2NO3 } on histocultured human patient bladder tumors and cancer cell line. Anticancer Res. 1996;16:3423-28.
58. New platinum complex compounds with reduced nephrotoxicity discovered in long-term histoculture of human renal cortical tissue. Anticancer Res. 1995;15:675-82.
59. Infections after renal transplantation. Transplant P. 1994;26:2072-74.
60. Comparison of glucose-consumption and thymidine-incorporation endpoints in histocultured human superficial bladder tumors. Anticancer Res. 1994;14:77-84.
61. The measurement of glucose consumption in histoculture to determine effects of doxorubicine and cisplatinum on human gastric carcinoma. Anticancer Res. 1993;13:1303-10.
62. Growth of human renal cortical tissue on collagen gel. In Vitro Cell Dev-An. 1992;28:128-35.
63. Long-term passage of human tissues in vitro as three dimensional histoline In Vitro Cell Dev-An. 1992;28:573-77.
64. Glucose consumption end points in primary histoculture indicates recovery of human tumors from drug treatment. In Vitro Cell Dev-An. 1992;28:585-87.
|
|
|
|
|
| |
|
|
| |
¼ö¼úµ¿¿µ»ó |
|
| |
|
|
|
|
|
|
| |
include ("../../include/busok_foot.php"); ?> |